Source comparison
TB-500 Dosage for Tissue Repair: Protocol Comparison
Acute muscle strain (Grade II–III) 7.5–10mg twice weekly (15–20mg/week) 5mg twice weekly (10mg/week) 140–160mg over 12 weeks Veterinary trials in equine muscle injury; human observational case series Highest dose range justified by rapid cellular migration req
This comparison does not assign a generated winner or score.
- Acute muscle strain (Grade II–III)
- 7.5–10mg twice weekly (15–20mg/week)
- 5mg twice weekly (10mg/week)
- 140–160mg over 12 weeks
- Veterinary trials in equine muscle injury; human observational case series
- Highest dose range justified by rapid cellular migration requirements during acute inflammatory resolution
- Chronic tendinopathy (patellar, Achilles)
- 2.5–5mg twice weekly (5–10mg/week)
- 2.5mg twice weekly (5mg/week)
- 60–100mg over 12 weeks
- Limited human case reports; extrapolated from collagen remodeling timelines in animal models
- Lower sustained dosing matches slower collagen turnover in degenerative tendon conditions
- Post-surgical repair (rotator cuff, ACL reconstruction)
- 100–120mg over 12 weeks
- Surgical wound healing studies in veterinary contexts; Phase I safety data in post-operative humans
- Mid-range protocol balances organized healing phases with cost-effectiveness
- Ligament partial tear (MCL, deltoid ligament)
- 5–7.5mg twice weekly (10–15mg/week)
- 120–140mg over 12 weeks
- Extrapolated from tendon repair data; ligament vascular supply parallels tendon tissue
- Dose adjusted upward from tendon protocols due to ligament's lower intrinsic healing capacity
- The comparison shows meaningful variation in both loading intensity and total cumulative dose across injury types. Acute injuries demand front-loaded high-dose protocols because the therapeutic window. Peak cellular migration and angiogenesis. Is narrow and time-sensitive. Chronic injuries tolerate (and may benefit from) lower sustained dosing because the goal is incremental tissue remodeling, not rapid repair.